News
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...
Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.
2h
Zacks Investment Research on MSNEli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should KnowEli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
The question is Wall Street’s version of white noise.When you’re stumped or don’t have the time or simply don’t want to make ...
Eli Lilly's stock recently took a hit, leaving investors scrambling like pharmacists out of espresso. The company’s ...
Wealth Enhancement Advisory Services LLC boosted its stake in Eli Lilly by grabbing an extra 15,393 shares, totaling a ...
Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...
In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...
The stock has dropped to its lowest level in four years compared to the U.S. energy index, which has reversed the gains from ...
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results